237 related articles for article (PubMed ID: 24040994)
1. Evaluation of the carcinogenicity of inorganic arsenic.
Cohen SM; Arnold LL; Beck BD; Lewis AS; Eldan M
Crit Rev Toxicol; 2013 Oct; 43(9):711-52. PubMed ID: 24040994
[TBL] [Abstract][Full Text] [Related]
2. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
[TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment of lung and bladder cancer risk and oral exposure to inorganic arsenic: Meta-regression analyses of epidemiological data.
Lynch HN; Zu K; Kennedy EM; Lam T; Liu X; Pizzurro DM; Loftus CT; Rhomberg LR
Environ Int; 2017 Sep; 106():178-206. PubMed ID: 28625818
[TBL] [Abstract][Full Text] [Related]
4. Arsenic-induced bladder cancer in an animal model.
Cohen SM; Ohnishi T; Arnold LL; Le XC
Toxicol Appl Pharmacol; 2007 Aug; 222(3):258-63. PubMed ID: 17109909
[TBL] [Abstract][Full Text] [Related]
5. Use of mode of action data to inform a dose-response assessment for bladder cancer following exposure to inorganic arsenic.
Gentry PR; Yager JW; Clewell RA; Clewell HJ
Toxicol In Vitro; 2014 Oct; 28(7):1196-205. PubMed ID: 24937311
[TBL] [Abstract][Full Text] [Related]
6. Arsenic exposure and bladder cancer: quantitative assessment of studies in human populations to detect risks at low doses.
Tsuji JS; Alexander DD; Perez V; Mink PJ
Toxicology; 2014 Mar; 317():17-30. PubMed ID: 24462659
[TBL] [Abstract][Full Text] [Related]
7. Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment.
Kitchin KT; Conolly R
Chem Res Toxicol; 2010 Feb; 23(2):327-35. PubMed ID: 20035570
[TBL] [Abstract][Full Text] [Related]
8. Dose-response for assessing the cancer risk of inorganic arsenic in drinking water: the scientific basis for use of a threshold approach.
Tsuji JS; Chang ET; Gentry PR; Clewell HJ; Boffetta P; Cohen SM
Crit Rev Toxicol; 2019 Jan; 49(1):36-84. PubMed ID: 30932726
[TBL] [Abstract][Full Text] [Related]
9. Comparative toxicity of arsenic metabolites in human bladder cancer EJ-1 cells.
Naranmandura H; Carew MW; Xu S; Lee J; Leslie EM; Weinfeld M; Le XC
Chem Res Toxicol; 2011 Sep; 24(9):1586-96. PubMed ID: 21815631
[TBL] [Abstract][Full Text] [Related]
10. Diuron-induced rat urinary bladder carcinogenesis: mode of action and human relevance evaluations using the International Programme on Chemical Safety framework.
Da Rocha MS; Arnold LL; De Oliveira ML; Catalano SM; Cardoso AP; Pontes MG; Ferrucio B; Dodmane PR; Cohen SM; De Camargo JL
Crit Rev Toxicol; 2014 May; 44(5):393-406. PubMed ID: 24512549
[TBL] [Abstract][Full Text] [Related]
11. Dietary administration of sodium arsenite to rats: relations between dose and urinary concentrations of methylated and thio-metabolites and effects on the rat urinary bladder epithelium.
Suzuki S; Arnold LL; Pennington KL; Chen B; Naranmandura H; Le XC; Cohen SM
Toxicol Appl Pharmacol; 2010 Apr; 244(2):99-105. PubMed ID: 20045014
[TBL] [Abstract][Full Text] [Related]
12. Low-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysis.
Mink PJ; Alexander DD; Barraj LM; Kelsh MA; Tsuji JS
Regul Toxicol Pharmacol; 2008 Dec; 52(3):299-310. PubMed ID: 18783726
[TBL] [Abstract][Full Text] [Related]
13. Evidence for toxicity differences between inorganic arsenite and thioarsenicals in human bladder cancer cells.
Naranmandura H; Ogra Y; Iwata K; Lee J; Suzuki KT; Weinfeld M; Le XC
Toxicol Appl Pharmacol; 2009 Jul; 238(2):133-40. PubMed ID: 19442679
[TBL] [Abstract][Full Text] [Related]
14. Inorganic arsenic: A non-genotoxic carcinogen.
Cohen SM; Chowdhury A; Arnold LL
J Environ Sci (China); 2016 Nov; 49():28-37. PubMed ID: 28007178
[TBL] [Abstract][Full Text] [Related]
15. Carcinogen exposure and epigenetic silencing in bladder cancer.
Marsit CJ; Karagas MR; Schned A; Kelsey KT
Ann N Y Acad Sci; 2006 Sep; 1076():810-21. PubMed ID: 17119258
[TBL] [Abstract][Full Text] [Related]
16. Bayesian benchmark dose analysis for inorganic arsenic in drinking water associated with bladder and lung cancer using epidemiological data.
Shao K; Zhou Z; Xun P; Cohen SM
Toxicology; 2021 May; 455():152752. PubMed ID: 33741492
[TBL] [Abstract][Full Text] [Related]
17. Characterization of intracellular inclusions in the urothelium of mice exposed to inorganic arsenic.
Dodmane PR; Arnold LL; Muirhead DE; Suzuki S; Yokohira M; Pennington KL; Dave BJ; Lu X; Le XC; Cohen SM
Toxicol Sci; 2014 Jan; 137(1):36-46. PubMed ID: 24097667
[TBL] [Abstract][Full Text] [Related]
18. Physiologically based pharmacokinetic modeling of arsenic in the mouse.
Gentry PR; Covington TR; Mann S; Shipp AM; Yager JW; Clewell HJ
J Toxicol Environ Health A; 2004 Jan; 67(1):43-71. PubMed ID: 14668111
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of action for arsenic in cardiovascular toxicity and implications for risk assessment.
Sidhu MS; Desai KP; Lynch HN; Rhomberg LR; Beck BD; Venditti FJ
Toxicology; 2015 May; 331():78-99. PubMed ID: 25771173
[TBL] [Abstract][Full Text] [Related]
20. Inorganic arsenic-induced intramitochondrial granules in mouse urothelium.
Suzuki S; Arnold LL; Muirhead D; Lu X; Le XC; Bjork JA; Wallace KB; Ohnishi T; Kakiuchi-Kiyota S; Pennington KL; Cohen SM
Toxicol Pathol; 2008 Dec; 36(7):999-1005. PubMed ID: 19126794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
